← All Sponsors
SPONSOR

Phanes Therapeutics

Total Trials
1
Recruiting
1
Phases
Phase 1, Phase 2
Conditions studied: Non Small Cell Lung CancerPancreatic Ductal Adenocarcinoma
NCT05431270 Phase 1, Phase 2
Recruiting

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Non Small Cell Lung Cancer
United States View Trial →